The Landscape of Amyloid-Targeting Therapeutics in Alzheimer's Disease Part 1: Anti-Amyloid Approaches
References
- Vitek GE, Decourt B, Sabbagh MN. Lecanemab (BAN2401): an anti-beta-amyloid monoclonal antibody for the treatment of Alzheimer disease. Expert Opin Investig Drugs. 2023 Feb;32(2):89–94. doi: 10.1080/13543784.2023.2178414. Epub 2023 Feb 28. PMID: 36749830; PMCID: PMC10275297.
- van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023 Jan 5;388(1):9–21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29. PMID: 36449413.
- European Medicines Agency. Kisunla (donanemab): EPAR overview. EMA; 2024. Available from:
https://www.ema.europa.eu/en/medicines/human/EPAR/kisunla - Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023 Aug 8;330(6):512–527. doi: 10.1001/jama.2023.13239. PMID: 37459141; PMCID: PMC10352931.
- ClinicalTrials.gov. TRAILBLAZER-ALZ 2 (NCT04437511). Available from:
https://clinicaltrials.gov/study/NCT04437511 . - U.S. Food and Drug Administration. FDA approves treatment for adults with Alzheimer's disease [donanemab]. FDA; 2024. Available from:
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-adults-alzheimers-disease . - DrugBank. Aducanumab (DB12274). Available from:
https://go.drugbank.com/drugs/DB12274 . - Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, Dent G, et al. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease. J Prev Alzheimers Dis. 2022;9(2):197–210. doi: 10.14283/jpad.2022.30. PMID: 35542991.
- ClinicalTrials.gov. EMERGE (NCT02484547). Available from:
https://clinicaltrials.gov/study/NCT02484547 . - Sperling RA, Donohue MC, Raman R, Rafii MS, Johnson K, Masters CL, et al. Trial of Solanezumab in Preclinical Alzheimer's Disease. N Engl J Med. 2023 Sep 21;389(12):1096–1107. doi: 10.1056/NEJMoa2305032. Epub 2023 Jul 17. PMID: 37458272; PMCID: PMC10559996.
- ClinicalTrials.gov. A4 Study (NCT02008357). Available from:
https://clinicaltrials.gov/study/NCT02008357 . - Cummings J, Osse AML, Cammann D, Powell J, Chen J. Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease. BioDrugs. 2024 Jan;38(1):5–22. doi: 10.1007/s40259-023-00633-2. Epub 2023 Nov 13. PMID: 37955845; PMCID: PMC10789674.
- Kaur M, Misra S. Remternetug: an investigational monoclonal antibody against β-amyloid for the treatment of Alzheimer's disease (AD). Int J Curr Pharm Res. 2025;17(3):7–9. doi: 10.22159/ijcpr.2025v17i3.55038.
- ClinicalTrials.gov. TRAILRUNNER-ALZ 1 (NCT05463731). Available from:
https://clinicaltrials.gov/study/NCT05463731 . - ClinicalTrials.gov. TRAILRUNNER-ALZ 3 (NCT06653153). Available from:
https://clinicaltrials.gov/study/NCT06653153 . - ClinicalTrials.gov. DIAN-TU (NCT05552157). Available from:
https://clinicaltrials.gov/study/NCT05552157 . - AlzForum. ALZ-801. Available from:
https://www.alzforum.org/therapeutics/alz-801 . - Tolar M, Hey J, Power A, Abushakra S. Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression. Int J Mol Sci. 2021 Jun 14;22(12):6355. doi: 10.3390/ijms22126355. PMID: 34198582; PMCID: PMC8231952.
- Tian J, Dang H, Wallner M, Olsen R, Kaufman DL. Homotaurine, a safe blood-brain barrier permeable GABAA-R-specific agonist, ameliorates disease in mouse models of multiple sclerosis. Sci Rep. 2018 Nov 8;8(1):16555. doi: 10.1038/s41598-018-32733-3. PMID: 30410049; PMCID: PMC6224391.
- ClinicalTrials.gov. APOLLOE4 (NCT04770220). Available from:
https://clinicaltrials.gov/study/NCT04770220 . - Abushakra S, Power A, Watson D, Porsteinsson A, Sabbagh M, MacSweeney E, et al. Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEɛ4/ɛ4 Homozygotes with Early Alzheimer's Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 Trial. Drugs. 2025 Nov;85(11):1455–1472. doi: 10.1007/s40265-025-02250-5. Epub 2025 Sep 28. PMID: 41015981; PMCID: PMC12572085.
- ClinicalTrials.gov. Long-term extension of APOLLOE4 (NCT06304883). Available from:
https://clinicaltrials.gov/study/NCT06304883
Language: English
Page range: 53 - 70
Accepted on: May 4, 2026
Published on: Jun 11, 2026
Published by: The Medical Library named after S. Konopka in Warsaw
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
Related subjects:
© 2026 Oliwier Szewczyk, Małgorzata Wojsław, Michał Pstrągowski, published by The Medical Library named after S. Konopka in Warsaw
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.